ClearBridge Large Cap Growth Select ETF (LRGE)
Live price chart, market sentiment, and community perspectives for ClearBridge Large Cap Growth Select ETF (NASDAQ: LRGE).
Live price chart, market sentiment, and community perspectives for ClearBridge Large Cap Growth Select ETF (NASDAQ: LRGE).
On our desk, we are closely tracking the Franklin Templeton reorganization moving CACG into LRGE. With total assets sitting around $380 million and a net expense ratio of 0.48%, the fund is consolidating its footprint. Market sentiment remains cautiously constructive, backed by an absence of aggressive shorting as short interest dropped by 57.5% over July.
As an asset allocator evaluating large growth vehicles, I note that LRGE benefits from secular tailwinds in AI-related investments and strong corporate earnings. However, the recent quarterly underperformance highlights how benchmark disruptions like the Russell reconstitution and historic IPO events can create interim tracking errors that require active management patience.
Looking at the portfolio metrics from a risk management perspective, the shift to a non-diversified mandate gives the ClearBridge team greater flexibility to express high-conviction views, but it also spikes single-name concentration risks. While Morningstar assigns LRGE a Neutral Medalist rating, we need to monitor how the strategy navigates ongoing volatility tied to AI infrastructure leadership and software sector rotations.
From a quantitative angle, the underlying portfolio turnover of 38% and a trailing 12-month yield of 0.12% reflect a pure large-cap growth posture. In our models, the strategy's ability to outperform in a risk-off quarter through diversified contributions outside of mega-cap technology provides a strong baseline for alpha generation in the second half of 2026.
On our options desk, the steep contraction in short interest—down 57.5% in July—tells us that bearish speculators are clearing out. With NAV hovering around $88.19 and a 1-day return showing positive momentum, the immediate downside pressures seen earlier in the quarter seem largely priced in or abandoned by short sellers.
Explore plasma cleansing, somatic organ swaps, and BCI.